Samsung Biologics celebrates 14th anniv. as world’s top CDMO

A Samsung Biologics researcher tests equipment at the company's plant No. 4 in Incheon in this undated handout photo released Monday. Courtesy of Samsung Biologics
Samsung Biologics celebrated the 14th anniversary of its founding on Monday, marking its rise to become the world’s largest contract development and manufacturing organization (CDMO).
After surpassing 4 trillion won ($2.82 billion) in annual sales last year, the biotech is aiming for the 5 trillion won mark this year, boosted by a 2 trillion won order secured in January.
Samsung Biologics was founded in 2011 as a result of Samsung Group’s efforts to diversify its portfolio by entering the biopharmaceutical industry. Despite the late entry, the company quickly rose in the CDMO industry for its competitiveness in quality and by securing large-scale production capacity.
During the past 14 years, the company has secured a total production capacity of 784,000 liters, the largest in the global CDMO industry. The biotech has secured over 350 manufacturing approvals from regulatory authorities around the world so far, and the number of its employees has grown to over 5,000 from 110 in 2011.
As of last year, the company has clinched 99 contract manufacturing deals and 133 contract development deals, whose combined value totals $16.3 billion. Among the world’s top 20 pharmaceutical companies, 17 are now contracting Samsung Biologics as a manufacturer or developer.
Buoyed by the solid orders, the company in 2022 became the first in Korea’s biopharmaceutical sector to surpass 3 trillion won in annual sales and exceeded the 4 trillion won mark last year.
The company now expects a 20 to 25 percent growth in sales this year, pushing its annual revenue above 5 trillion won. The rosy outlook is supported by a 2.07 trillion won contract manufacturing deal it secured in January from a Europe-based biopharmaceutical firm.
Samsung Biologics' plant No. 4 in Incheon / Courtesy of Samsung Biologics
Going forward, Samsung Biologics plans to build three additional plants by 2032 to increase the total number of its manufacturing facilities to eight. Once all eight plants are completed, the company’s total production capacity will reach 1.324 million liters.
In doing so, it also plans to diversify its portfolio. Samsung Biologics last month began operations at a dedicated facility for the production of antibody-drug conjugates, which are viewed as one of the most promising cancer therapies.
The company currently operates sales offices in New Jersey and Tokyo and said it will expand its global presence in the future.
“For the past 14 years, Samsung Biologics has been leading the CDMO market by providing the best quality and service to global clients,” Samsung Biologics CEO John Rim said. “We will continue to make preemptive investments to strengthen our competitiveness further and will spare no effort to materialize our vision for a better life of humanity.”